Waiting more than three months for nephrectomy was linked to higher cancer mortality

Design

Retrospective SEER cohort with propensity matching and competing-risks regression

Population

16,322 patients with pT1b–2 N0 M0 renal cell carcinoma, 2004–2021

Primary outcome

Cancer-specific mortality

Effect

Five-year CSM 7.6% vs 5.9% for >3 vs ≤3 months to surgery; about 1.3-fold higher hazard (P = 0.02)

This SEER analysis, published in BJU International on 29 September, included 16,322 patients with pT1b–2, node-negative, non-metastatic renal cell carcinoma treated by partial or radical nephrectomy between 2004 and 2021. Eighteen per cent waited more than three months for surgery.

After propensity matching, five-year cancer-specific mortality was 7.6% with a wait over three months against 5.9% with a shorter wait, and delay was independently associated with about 1.3-fold higher mortality. The effect grew with longer waits (about 1.6-fold beyond six months) and held across grades, but was not seen in non-clear-cell tumours.

For T1a tumours, active surveillance is established. For larger localised tumours, these data argue against letting surgery drift. Where waiting lists run beyond three months, larger clear-cell tumours may deserve priority.

• Aim to operate on localised pT1b–2 renal tumours within three months of diagnosis.
• Prioritise larger clear-cell tumours on waiting lists.
• Record the diagnosis date so waiting time can be audited.
• Do not extend this finding to small T1a masses, where surveillance is established.

Why it matters

A delay that often feels harmless for a localised kidney tumour was linked to measurably worse survival.

Don't overread it

This was observational registry data; staging is pathological, so the tumour's size at diagnosis is not known.

The statistics, in plain English

A 1.7 percentage-point difference in five-year cancer-specific mortality (7.6% vs 5.9%) means about one or two extra cancer deaths per 100 patients who waited. The 1.3-fold figure is a relative hazard from a competing-risks model.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.